Fibrogenesis & Tissue Repair · 2014 · 32 citations · 29 references
MedicineMolecular MedicineCell TherapyNeuromuscular DisordersRegenerative MedicineFibrosisMuscle DisordersMuscle MechanicsMuscle PathologyMuscle TissueMuscular DystrophyFatigue ResistanceFibrosis ReductionFibrotic ChangeMuscle DamageMuscle RegenerationMuscular Dystrophy PathophysiologySkeletal Muscle WastingSkeletal Myopathy
BACKGROUND: Duchenne muscular dystrophy (DMD) is a severe and progressive muscle-wasting disorder caused by mutations in the dystrophin gene that result in the absence of the membrane-stabilising protein dystrophin. Dystrophic muscle fibres are susceptible to injury and degeneration, and impaired muscle regeneration is associated with fibrotic deposition that limits the efficacy of potential pharmacological, cell- and gene-based therapies. Novel treatments that can prevent or attenuate fibrosis have important clinical merit for DMD and related neuromuscular diseases. We investigated the therapeutic potential for tranilast, an orally bioavailable anti-allergic agent, to prevent fibrosis in skeletal muscles of mdx dystrophic mice. RESULTS: Three-week-old C57Bl/10 and mdx mice received tranilast (~300 mg/kg) in their food for 9 weeks, after which fibrosis was assessed through histological analyses, and functional properties of tibialis anterior muscles were assessed in situ and diaphragm muscle strips in vitro. Tranilast administration did not significantly alter the mass of any muscles in control or mdx mice, but it decreased fibrosis in the severely affected diaphragm muscle by 31% compared with untreated mdx mice (P < 0.05). A similar trend of decreased fibrosis was observed in the tibialis anterior muscles of mdx mice (P = 0.10). These reductions in fibrotic deposition were not associated with improvements in maximum force-producing capacity, but we did observe small but significant improvements in the resistance to fatigue in both the diaphragm and TA muscles of mdx mice treated with tranilast. CONCLUSION: Together these findings demonstrate that administration of potent antifibrotic compounds such as tranilast could help preserve skeletal muscle structure, which could ultimately increase the efficacy of pharmacological, cell and gene replacement/correction therapies for muscular dystrophy and related disorders.
29
X chromosome-linked muscular dystrophy (mdx) in the mouse.
G. Bulfield, W. G. Siller, P.A.L. Wight et al. · Proceedings of the National Academy of Sciences · 1984 · 1.8K citations · Full text
The Molecular Basis of Muscular Dystrophy in the <i>mdx</i> Mouse: a Point Mutation
Piotr Siciński, Yan Geng, Allan S. Ryder-Cook et al. · Science · 1989 · 1.2K citations
The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy
Hansell H. Stedman, H. Lee Sweeney, Joseph B. Shrager et al. · Nature · 1991 · 916 citations
Medicine, Cell Biology, Neurology +12
Aberrant repair and fibrosis development in skeletal muscle
Christopher J. Mann, Eusebio Perdiguero, Yacine Kharraz et al. · Skeletal Muscle · 2011 · 845 citations · Full text